The orexin-1 receptor antagonist SB-334867 reduces motivation, but not inhibitory control, in a rat stop signal task
Abstract
There is considerable clinical interest in the neuropeptide orexin/hypocretin for its ability to regulate motivation and reward as well as arousal and wakefulness. For instance, antagonists for the orexin-1 receptor (OxR1) are thought to hold great promise for treating drug addiction and disorders associated with overeating, as these compounds repeatedly have been found to suppress seeking of various drugs of abuse as well as highly palatable foods in preclinical models. Given the hypothesized role of OxR1 signaling in cue-driven motivation, an outstanding question is whether pharmacologically blocking this receptor affects cognitive functioning. Response inhibition - the ability to cancel ongoing behavior - is one aspect of cognitive control that may be particularly relevant. Response inhibition deficits are commonly associated with a range of psychiatric disorders and neurological diseases, including substance use disorders and obesity. Moreover, OxR1 signaling recently has been implicated in waiting impulsivity, another aspect of inhibitory control. Here, we investigated the effects of the OxR1 antagonist SB-334867 on response inhibition in a rat version of the stop signal reaction time task. Results show that acutely blocking OxR1 had minimal effects on response inhibition or attentional functioning. In contrast, this manipulation reduced motivation to perform the task and earn food rewards. These results add to the growing body of literature implicating OxR1 in the regulation of motivation and suggest that effects of pharmacological compounds such as SB-334867 on drug seeking behavior are not related to effects on response inhibition.\n\nHighlightsO_LIOrexin-1 receptor antagonists hold great promise for treatment of drug addiction\nC_LIO_LIThese compounds are thought to reduce motivation for drug seeking\nC_LIO_LILess is known about effects of orexin-1 receptor blockade on cognitive functioning\nC_LIO_LIWe tested the orexin-1 receptor antagonist SB-334867 in a rat stop signal task\nC_LIO_LISB-334867 reduced task motivation but had little effect on executive control as measured with response inhibition\nC_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 29
- FWCI
- 2.98
- Field percentile
- top 8%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil
A. Mohammadkhani, M. James, G. Aston-Jones·bioRxiv·Jan 17, 2019
- The Role of Orexin-1 Receptor Signaling in Demand for the Opioid Fentanyl
J. E. Fragale, C. B. Pantazis, … G. Aston-Jones·bioRxiv·Jan 31, 2019
- Orexin-1 receptor signaling in ventral pallidum regulates demand for the opioid remifentanil
A. Mohammdkhani, C. B. Pantazis, … G. Aston-Jones·The Journal of NeurosciencePeer-reviewed·Oct 22, 2019
- The dual orexin/hypocretin receptor antagonist suvorexant reduces addiction-like behaviors for the opioid fentanyl
Shayna L. O’Connor, Jennifer E. C. Fragale, … Gary Aston‐Jones·bioRxiv·Apr 25, 2020
- Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin/hypocretin-1 receptor antagonist in rats
Morgan H. James, Hannah E. Bowrey, … Gary Aston‐Jones·European Journal of NeurosciencePeer-reviewed·Sep 22, 2018
- Dual Hypocretin Receptor Antagonism Reduces Oxycodone Seeking During Abstinence
Kyle R. Samson, Alison R. Bashford, Rodrigo A. España·bioRxiv·Apr 5, 2025